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Maternal use of selective serotonin
reuptake inhibitors during pregnancy is
associated with Hirschsprung’s disease in
newborns – a nationwide cohort study
Sebastian Werngreen Nielsen1,3*, Perniller Møller Ljungdalh2, Jan Nielsen2, Bente Mertz Nørgård2 and Niels Qvist1
Abstract
Background: Hirschsprung’s disease is a rare condition caused by congenital malformation of the gastrointestinal
tract affecting 1:5000 children. Not much is known about risk factors for development of Hirschsprung’s disease.
Two clinical cases of hirschsprung’s disease led to an investigation of the association between maternal use of
selective serotonin reuptake inhibitors (SSRIs) during pregnancy and development of Hirschsprung’s Disease in
the newborn child. The study examined a nationwide, unselected cohort of children born in Denmark from 1
January 1996 until 12 March 2016 (n = 1,256,317). We applied multivariate models to register-based data to
estimate the odds ratio of Hirschsprung’s disease, adjusting for possible confounders. The studied exposure
period for SSRIs were 30 days prior to conception to the end of the first trimester.
Results: In the main exposed cohort the prevalence of Hirschsprung’s disease was 16/19.807 (0.08%) compared
to 584/1.236.510 (0.05%) in the unexposed cohort. In women who redeemed a minimum of one prescription of
selective serotonin reuptake inhibitors, the adjusted odds ratio for development of Hirschsprung’s disease was
1.76 (95%CI: 1.07–2.92). In women who redeemed a minimum of two prescriptions, the adjusted odds ratio
for Hirschsprung’s disease was 2.34 (95% CI: 1.21–4.55).
Conclusions: Our data suggest that early maternal use of selective serotonin reuptake inhibitors is significantly
associated with the development of Hirschsprung’s disease in the newborn child. Treatment of depression during
pregnancy always has to be weighed against the risks posed by untreated maternal depression. Our results have
to be confirmed in other studies.
Keywords: SSRI, Congenital malformation, Hirschsprung’s disease, Developmental biology, Enteric nervous
system, Paediatric gastroenterology
Background
The use of selective serotonin inhibitors (SSRIs) during
pregnancy has increased significantly during the last
two decades [1–3] and an increased risk of adverse
birth outcomes has been reported, [4, 5] including neo-
natal complications [5], and groups of congenital heart
and gastrointestinal malformations [4, 6–12]. Other
studies have not found an increased risk of malforma-
tions [13–15].
Serotonin or 5-hydroxytryptamine (5-HT) is a monoa-
mine neurotransmitter, which is important for the deve-
lopment of the enteric nervous system, and the migration
of neural crest cells to the bowel wall during the first
trimester [16–18]. SSRI intake during the first trimester
might inhibit this process resulting in Hirschsprung’s di-
sease (HD). HD is a congenital malformation with agan-
glionosis of the enteric plexuses of the bowel wall that
extends from the anal canal and proximally affecting a
variable length of the colon. The clinical picture is ileus
* Correspondence: sebastian@werngreen.com
1Department of Surgical Gastroenterology A, Odense University Hospital, and
Research Unit of Surgery, Institute of Clinical Research, University of Southern
Denmark, 5000 Odense C, DK, Denmark
3Engelshøjgade 26 1TH, 6400 Sønderborg, Denmark
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Nielsen et al. Orphanet Journal of Rare Diseases  (2017) 12:116 
DOI 10.1186/s13023-017-0667-4
with megacolon or intractable constipation, which neces-
sitates surgery in infancy or childhood [19] resulting in se-
vere consequences of impaired bowel function with a
mixture of constipation and in faecal incontinence in early
life and later [20].
During the last decade the incidence of HD has dou-
bled [21, 22] and since only a minority of HD cases have
a known genetic aetiology, further investigation into
non-genetic risk factors of HD is warranted [23].
The aim of the present study was to investigate the as-
sociation between maternal prescription of SSRI in the
period of 1 month prior to conception to the end of first
trimester of pregnancy and having a child with the diag-
nosis of HD. To examine this association we used na-
tionwide Danish register data.
Methods
Setting
A population-based nationwide cohort study was con-
ducted using data from Danish health registries. The uni-
form organization and unrestricted access to a tax-funded
universal healthcare system for all Danish residents,
allowed us to use a population-based study design. We
used the Danish National Patient Registry (NPR) [24], the
Danish Medical Birth Registry (MBR) [25], the Nationwide
Prescription Database [26], and the Central Personal
Registration system [27]. All registries were linked using
the civil registration number. All Danish residents are
assigned a civil registration number at birth or when ta-
king residence in Denmark, and this unique identifier was
unambiguously used to link data on an individual level.
Study population
The study population included all live born children
identified by the Medical Birth Registry [25] with a valid
civil registration in Denmark from 1 January 1996 until
12 March 2016. By using information on the gestational
age and delivery date, the date of conception was
assessed for all children in the study population.
Data sources
Established in 1977, the NPR includes records of all dis-
charges from Danish hospitals and since 1994 all out-
patient visits. Information in the NPR includes patients’
civil registration numbers and up to 20 discharge diagno-
ses based on the International Classification of Diseases
(ICD-10 from 1994 onward) [24, 28]. The MBR consists
of information on all births in Denmark since 1973 in-
cluding pregnancy-related information i.e. gestational age,
birth outcomes, and information on the mother, maternal
civil registration number, maternal age, smoking status
and parity. In 1997 the coding of maternal smoking was
expanded to include possible registration of maternal
smoking cessation during pregnancy. As this change was
done during the study period, we reduced the complexity
of the variable maternal smoking to yes (including any
smoking and smoking cessation during pregnancy), no
(no smoking whatsoever) [25].
The Danish Medicine Agency maintains a nationwide
prescription database for all reimbursed drug prescrip-
tions issued from Danish pharmacies. The database in-
cludes for each prescription, patients’ civil registration
number, medication dosage, package size, date of reim-
bursement and drug classification code, according to the
anatomical therapeutic chemical (ATC) classification sys-
tem [29]. As only prescription drugs are registered in the
Nationwide Prescription Database, over-the-counter-sale
is not included. However, SSRI are only available by pre-
scription in Denmark. The Central Personal Registration
system consists of information on civil registration num-
ber, death and immigration.
Exposed cohort, children born of women exposed to SSRI
Main cohort
For the children in the study population, information
was collected on maternal prescriptions of SSRI (ATC:
N06AB03, N06AB04, N06AB05, N06AB06, N06AB08,
N06AB10) from 30 days before conception to end of
first trimester (end of 12th week of pregnancy). The
main exposed cohort, thus, included children of women
who had filled one or more prescriptions from 30 days
before conception to end of first trimester.
Sub-cohort I
Sub-cohort I was defined as all children in the main
cohort where the mothers filled one single SSRI pre-
scription from 30 days before conception to end of first
trimester.
Sub-cohort II
Sub-cohort II was defined as all children in the main
cohort where the mothers filled two or more SSRI pre-
scriptions from 30 days before conception to end of first
trimester.
Unexposed cohort, children born of women not exposed
to SSRI
The unexposed cohort constituted all children included
in the study population where mothers did not fill pre-
scriptions of SSRI from 30 days before conception to
end of first trimester.
Outcome
Outcome information was obtained from the NPR and
defined as any child with a diagnosis of HD (ICD-10:
DQ431) from 1 January 1996 until 12 March 2016.
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Information on possible confounders
From the Maternal Birth Registry (MBR) [25], we ob-
tained information on the age of the mother (≤19, 20–
24, 25–29, 30–34 ≥ 35 years) at the time of delivery, par-
ity (one or more than one pregnancy), sex of the child,
maternal smoking during pregnancy (yes/no), and calen-
dar year of birth (1996–2001, 2002–2007, 2008–2011,
2012–2016).
Statistical analysis
We constructed contingency tables for the main study
variables according to the exposed and unexposed co-
horts. We used logistic regression analyses to compute
crude and adjusted odds ratio estimates (prevalence
odds ratio with 95% confidence intervals [95% CI]) for
HD following maternal use of SSRI relative to no mater-
nal use of SSRI. These analyses were performed for the
main cohort, sub-cohort I, and sub-cohort II, all relative
to the unexposed cohort.
Adjustment was made for maternal age (≤19, 20–24,
25–29, 30–34 ≥ 35 years), maternal smoking status (yes/
no), parity (one or more than one pregnancy), sex of the
child, and calendar year of birth (1996–2001, 2002–
2007, 2008–2011, 2012–2016).
Sub-analysis
To exclude an underlying effect of other maternal di-
sease that might be associated with malformations and
use of SSRI we performed a sub-analysis. We excluded
children from the exposed and unexposed cohort where
the mothers had reimbursed prescriptions for any of the
following medications: antiepileptic drugs (ATC: N03A),
antidiabetic drugs (ATC: A10), antipsychotic drugs
(ATC: N05A), anxiolytics (ATC: N05B), and tricyclic
antidepressants (ATC:N06AA) 3 months prior to con-
ception and until the end of 12th week of pregnancy.
Again we used logistic regression analyses to compute
crude and adjusted odds ratio estimates for HD follo-
wing maternal use of SSRI, and included in the model
were the same covariates as in the main analyses.
All calculations were performed using STATA Release
14.0 (StataCorp, College Station, TX, USA).
Results
A total of 1.256.317 children were included, and of
these, 19.807 children were born by women who had
filled one or more prescriptions of SSRIs 30 days before
conception to the end of the first trimester. Sub-cohort I
included 11.351 children born by women who had filled
only one SSRI prescription within30 days before concep-
tion to the end of the first trimester, and sub-cohort II
included 8.456 children born by women who had filled
two or more SSRI prescriptions within 30 days before
conception to the end of the first trimester. A total of
1.236.510 children were born by mothers who were not
exposed to SSRI 30 days before conception to the end of
the first trimester. The characteristics of the exposed
and unexposed cohorts are shown in Table 1, and the
basic characteristics were similar according to mother’s
age at delivery, sex of child and parity. Maternal smo-
king was more frequent in the main exposed cohort
(28.6%) compared to the unexposed cohort (15.1%).
In the main exposed cohort we found that 16 out of
19.807 (0.08%) of the children had a diagnosis of HD,
and among the unexposed cohort 584 out of 1.236.510
(0.05%) had HD, corresponding to an adjusted OR for
HD of 1.76 (95% CI 1.07–2.92) (Table 2). In sub-cohort I
(only one redeemed prescription), 7 out of 11.351
(0.06%) had a diagnosis of HD (corresponding to an ad-
justed OR for HD of 1.33 (95% CI 0.63–2.83) (Table 2).
In children in sub-cohort II (a minimum of two
redeemed prescriptions), 9 out of 8.456 (0.11%) had a
diagnosis of HD, and the adjusted OR for HD was 2.34
(95% CI 1.21–4.55) (Table 2).
In our sub-analysis we excluded women with prescrip-
tions of antiepileptic, antidiabetic, antipsychotics, anxio-
lytic and tricyclic antidepressants, and a total of 16.395
children were born by women who had filled one or
more prescription of SSRI 30 days before conception to
the end of the first trimester. A total of 1.207.989 chil-
dren were born to women not exposed to SSRI. The
basic characteristics were similar between the exposed
and unexposed (Additional file 1). A total of 13 children
were born with HD out of 16.395 (0.08%), corresponding
to an adjusted OR for HD of 1.76 (95% CI 1.01–3.07)
(Table 3). In sub-cohort I, a total of 6 children had HD
out of 9.663 (0.06%) corresponding to an adjusted OR
for HD of 1.38 (95% CI 0.61–3.09). In sub-cohort II, a
total of 7 children had HD out of 6.732 (0.10%), corre-
sponding to an OR for HD of 2.32 (95% CI 1.10–4.91)
(Table 3).
Discussion
The results of our study demonstrated a significantly in-
creased risk of HD after maternal exposure to SSRI. The
analyses indicated that only one redeemed prescription
for SSRI was associated to a 1.3 fold increased risk of HD,
and a minimum of two redeemed prescriptions was asso-
ciated to a 2.3 increased risk, indicating a dose-response
relationship between SSRI and development of HD.
A review of the literature did not yield any previous
studies that demonstrated an association between mater-
nal use of SSRIs and HD. The majority of population-
based studies examined different groups of congenital
malformations [4, 6–10] and none have had specific
focus on the association between HD and SSRIs. The
aetiology of various congenital malformations differ, and
the clustering of gastrointestinal malformations in one
Nielsen et al. Orphanet Journal of Rare Diseases  (2017) 12:116 Page 3 of 7
group for analyses may render previous studies unable
to show a specific association between SSRIs and HD.
HD is a rare disease (1:5000 live births) and most of the
previous studies may lack the statistical power to find
significant associations between maternal use of SSRI
and specific malformations [4, 6, 8, 13, 14].
The strengths of the present study were that it was
based on nationwide registers and included information
on all children in Denmark during the study period. We
had no loss to follow up which prevents selection bias.
The information on maternal drug exposure was based
on prescriptions and not on patient recall therefore
Table 1 Characteristics of the exposed and unexposed cohorts. The exposed cohort was divided according to number of redeemed
prescriptions of selective serotonin-reuptake inhibitors (SSRI’s): minimum of one prescription, limited to one prescription, and
minimum two prescriptions. Total number of children, n = 1.256.317
SSRI prescriptions redeemed a
minimum of one time (n = 19,807)
SSRI prescriptions redeemed
one time only (n = 11.351)
SSRI prescriptions redeemed
minimum two times (n = 8.456)
No prescriptions of
SSRIs (n = 1.236.510)
Maternal age
≤19 308 (1.6%) 184 (1.6%) 124 (1.5%) 18.039 (1.5%)
20–24 2.645 (13.4%) 1.530 (13.5%) 1.115 (13.2%) 145.031 (11.7%)
25–29 5.764 (29.1%) 3.234 (28.5%) 2.530 (29.9%) 415.536 (33.6%)
30–34 6.678 (33.7%) 3.779 (33.3%) 2.899 (34.3%) 437.740 (35.4%)
≥35 4.412 (22.3%) 2.624 (23.1%) 1.788 (21.1%) 220.164 (17.8%)
Maternal smoking status
No 13.384 (67.6%) 7.838 (69.1%) 5.546 (65.6%) 946.853 (76.6%)
Yes 5.656 (28.6%) 3.095 (27.3%) 2.561 (30.3%) 186.807 (15.1%)
Missing 767 (3.9%) 418 (3.7%) 349 (4.1%) 102.850 (8.3%)
Sex of child
Male 10.249 (51.7%) 5.862 (51.6%) 4.387 (51.9%) 601.949 (48.7%)
Female 9.558 (48.3%) 5.489 (48.4%) 4.069 (48.1%) 634.561 (51.3%)
Parity
1 8.792 (44.4%) 4.912 (43.3%) 3.880 (45.9%) 545.646 (44.1%)
>1 11.015 (55.6%) 6.439 (56.7%) 4.576 (54.1%) 690.864 (55.9%)
Birth year
1996–2001 1.972 (10.0%) 1.033 (9.1%) 939 (11.1%) 387.716 (31.4%)
2002–2007 6.077 (30.7%) 2.976 (26.2%) 3.101 (36.7%) 376.939 (30.5%)
2008–2011 6.787 (34.3%) 3.952 (34.8%) 2.835(33.5%) 240.952 (19.5%)
2012–2016 4.971 (25.1%) 3.390 (29.9%) 1.581 (18.7%) 230.903 (18.7%)
Table 2 Odds ratio (OR) estimates for Hirschsprung’s Disease from logistic regression models, crude and adjusted OR with 95%
confidence interval (CI) for occurrence of Hirschsprung’s Disease based on all live births in the period of 1 january 1996 until 12
March 2016








Child born with Hirschsprung’s
Disease
16/19.807 (0.08%) 584/1.236.510 (0.05%) 1.71 (1.04–2.81) 1,76 (1.07–2.92)






Child born with Hirschsprung’s
Disease
7/11.351 (0.06%) 584/1.236.510 (0.05%) 1.31 (0.62–2.75) 1.33 (0.63–2.83)








Child born with Hirschsprung’s
Disease
9/8.456 (0.11%) 584/1.236.510 (0.05%) 2.25 (1,17–4.36) 2.34 (1.21–4.55)
aAdjusted for maternal age (≤19, 20–24, 25–29, 30–34, ≥35), maternal smoking (yes/no), sex, of child (male/female), parity (1/<1), calendar year of birth
(1996–2001, 2002–2007, 2008–2011, 2012–2016)
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eliminating recall bias. Information on the outcome
(HD) was collected independently of the exposure status
and thereby preventing information bias. In Denmark,
HD is treated in one of two national centres and internal
review of the HD diagnosis from one of these centres
(Odense University Hospital), verified that all HD diag-
noses from the NPR was given on the basis of histo-
pathological examination of rectal biopsies or surgical
specimens (unpublished data). The validity of the diag-
nosis of HD is therefore considered high. In our study
we had access to a complete nationwide prescription
database, ensuring that all mothers could be classified
according to the possible prescriptions for SSRIs during
the pre-conception period and during early pregnancy.
The data in the prescription database are of high quality
as previously documented [30]. Furthermore it is
strength that we, in sub-analyses, were able to eliminate
a possible confounding impact of other maternal under-
lying diseases that at least in the theory could be asso-
ciated to congenital malformations. In sub-analyses, we
thus excluded women using medications for epilepsy,
diabetes, and those who used antipsychotics, anxiolytics
and tricyclics antidepressants; and we found that our re-
sults were robust as the results from the sub-analyses
were similar to our main analyses. With regard to pos-
sible confounders, we were able to take into conside-
ration several possible confounders, but the impact of
these was limited as the crude and adjusted risk esti-
mates were similar. Overall, the external validity of our
study is considered good and applicable to other
populations.
Possible limitations of this study were lack of informa-
tion on drug compliance. We used prescription data as a
proxy for drug intake. Previous studies in pregnant
women indicated a high rate of compliance in the use of
antidiabetic, antibiotic and thyroid medication [31–33].
Patient compliance of antidepressant treatment in
Denmark has previously been estimated to 80% [34] and
similar findings were found in a Swedish study based on
patient interviews (83%) [35]. Any potential misclassifi-
cation of exposure due to patient non-compliance
would, however, tend to underestimate our risk esti-
mates. A high degree of non-compliance could therefore
mask a true association. In addition, we did not have
enough data to look into the impact of specific types of
SSRI. The few number of children born with HD among
exposed women did not allow us to give results accor-
ding to specific types of SSRIs. In a cohort study like
this, it may be difficult to isolate the effects of drug
treatment, and in case of a statistical significant associa-
tion (as in our study), it is necessary to consider whether
the result is influenced by residual or unmeasured con-
founding. We had no opportunity to adjust our analyses
for severity of underlying depression, and it is unknown
whether maternal depression may predispose to HD. An
association between major congenital malformation and
depression has not been documented [36–38] and HD-
associated genes do not match genes associated with de-
pression [39, 40]. Development of the enteric nervous
system is dependent on epigenetic stability [41] and ma-
ternal depression is associated with epigenetic changes
within the DNA of the offspring, including a gene en-
coding a trans membrane serotonin transporter that re-
gulates the intrasynaptic reuptake of serotonin. This
would lead to less intrasynaptic 5-HT, the exact opposite
effect of an SSRI, which increases intrasynaptic 5-HT
[42]. Other studies did not find epigenetic changes re-
lated to maternal depression [43].
HD phenotypes can arise from different genotypes
[44] and the genes associated with the most common
type of HD (short-segmented HD) are likely to have
possible environmental interactions [39, 45]. While
Table 3 Odds ratio (OR) estimates for Hirschsprung’s Disease from logistic regression models, crude and adjusted OR with 95%
confidence interval (CI) for occurrence of Hirschsprung’s Disease based on all live births in the period of 1 january 1996 until 12
March 2016. All women with prescriptions 3 months prior to time of conception of antiepileptic, antidiabetic, antipsychotics,
anxiolytic and tricyclic antidepressants are excluded from the population








Child born with Hirschsprung’s
Disease
13/16.395 (0.08%) 561/1.207.989 (0.05%) 1.71 (0.99–2.96) 1.76 (1.01–3.07)






Child born with Hirschsprung’s
Disease
6/9.663 (0.06%) 561/1.207.989 (0.05%) 1.34 (0.60–3.00) 1.38 (0.61–3.09)








Child born with Hirschsprung’s
Disease
7/6.732 (0.10%) 561/1.207.989 (0.05%) 2.24 (1.06–4.72) 2.32 (1.10–4.90)
aAdjusted for maternal age (≤19, 20–24, 25–29, 30–34, ≥35), maternal smoking (yes/no), sex, of child (male/female), parity (1/<1), calendar year of birth
(1996–2001, 2002–2007, 2008–2011, 2012–2016)
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discussing confounding by indication in relation to de-
pression and HD it is therefore important to note that
depression during pregnancy may be associated with
poor nutrition, obesity, smoking, alcohol, and drug abuse
[37, 38]. These risk factors can influence the develop-
ment of the enteric nervous system (causing HD, but the
relation between environmental risk factors and HD is
not well documented [21, 46]. Maternal smoking has
been linked to an increase in gastrointestinal malforma-
tions [47], but no association between smoking and HD
has been found [48]. One study has reported that vita-
min A deficiency (as a proxy for poor nutrition) can im-
pair development of the enteric nervous system and
cause a HD-like condition in mice [49]. This is interes-
ting since folic acid supplement compliance during preg-
nancy is poor especially in young, smoking women with
low levels of education [50]. No information on nutri-
tional habits including supplement of vitamins were in-
cluded in the present study. Maternal obesity may
increase the risk of HD [48], but it was not possible to
include this information in this study.
Conclusions
Our data suggest that use of SSRIs in the period of
30 days before conception to end of the first trimester is
associated to an increased risk of HD. We cannot rule
out that our results might be influenced by unknown
confounders, and we do not know whether the increased
risk of HD might be associated to specific types of SSRIs.
Our results need to be confirmed in other settings, and
in the future we need data on a possible impact of spe-
cific types of SSRIs. Treatment of depression during
pregnancy always has to be weighed against the risks
posed by untreated maternal depression during preg-
nancy, but restrain should be shown in fertile women,
who do not use effective contraceptive measures or are
planning to become pregnant.
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